Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough's Clarinex and Savient's Oxandrin Challenged By Paragraph IV Certifications

This article was originally published in The Pink Sheet Daily

Executive Summary

Schering-Plough's antihistamine franchise is facing Paragraph IV challenges. An ANDA for Clarinex(desloratadine) 5 mg tablets, as well as 2.5 mg and 5 mg orally disintegrating tablets, was filed on June 21. An ANDA was also filed for Clarinex-D 24 Hour extended release 5 mg/240 mg tablets. Clarinex 5 mg tablets and the orally disintegrating formulations are protected with a patent through Jan.7, 2020, including a pediatric extension, while patent protection for the extended release 5 mg/240 mg version runs through March 28, 2022, according to the "Orange Book." ANDAs with Paragraph IV certifications have also been filed for Savient's oral anabolic agent Oxandrin(oxandrolone) tablets 2.5 mg and 10 mg tablets. Both formulations are protected by patents through Dec. 5, 2015
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS064756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel